Literature DB >> 30276105

Trends in the Use of Bone Morphogenetic Protein-2 in Adult Spinal Deformity Surgery: A 10-Year Analysis of 54 054 Patients.

Rafael DE LA Garza Ramos1,2, Jonathan Nakhla1,2, Niketh Bhashyam1,2, Adam E Ammar1,2, Aleka N Scoco1,2, Merrit D Kinon1,2, Reza Yassari1,2.   

Abstract

BACKGROUND: Bone morphogenetic protein-2 (BMP-2) is an available bone graft option in spinal fusion surgery. The purpose of this study is to investigate the trends of BMP-2 utilization in adult spinal deformity (ASD) surgery.
METHODS: The Nationwide Inpatient Sample database from 2002 to 2011 was reviewed. Inclusion criteria were patients over 18 years of age who underwent spinal fusion for ASD. Trends of BMP-2 use were examined over time, as well as stratified based on patient and surgical characteristics. All analyses were done after application of discharge weights to produce national estimates.
RESULTS: There were 54 054 patients who met inclusion criteria and were included in this study. The overall rate of BMP-2 use was 39.7% (95% confidence interval 35.0%- 44.3%). Overall, there was steady increase in its use over time, with the highest peak in 2009 (55.3% of all cases used BMP-2), and then a decrease up to 37.9% in 2011 (P < .001). The rate of BMP-2 use was significantly higher for patients older than 54 years of age (compared to patients <54, P < .001). It was also higher in females (P = .009), Caucasian patients (P = .006), and Medicare patients (P = .006). Its use was 28.6% in the Northeast, 38.1% in the South, 45.2% in the Midwest, and 48.2% in the West (P = .035). Circumferential procedures had the highest rate of BMP-2 use (44.3%, P = .045). Average total hospital charges were $152,403 ± 117,454 for patients who did not receive BMP-2 and $205,426 ± 137,561 for patients who did (P < .001).
CONCLUSION: After analysis of a large nationwide database, it was found that the rate of BMP-2 use in ASD surgery is approximately 40%. There was a significant increase in use from 2002 to 2009, and a decrease thereafter. The highest rates of use were found in older patients, female patients, white patients, Medicare patients, circumferential approaches, and patients undergoing surgery in the Midwest and West regions.

Entities:  

Keywords:  Nationwide Inpatient Sample; adult spinal deformity; bmp-2; bone morphogenetic protein; trends

Year:  2018        PMID: 30276105      PMCID: PMC6159692          DOI: 10.14444/5054

Source DB:  PubMed          Journal:  Int J Spine Surg        ISSN: 2211-4599


  16 in total

1.  Bone: formation by autoinduction.

Authors:  M R Urist
Journal:  Science       Date:  1965-11-12       Impact factor: 47.728

2.  National Trends in the Surgical Management of Adult Lumbar Isthmic Spondylolisthesis: 1998 to 2011.

Authors:  Caroline P Thirukumaran; Brandon Raudenbush; Yue Li; Robert Molinari; Paul Rubery; Addisu Mesfin
Journal:  Spine (Phila Pa 1976)       Date:  2016-03       Impact factor: 3.468

3.  Pseudarthrosis in adult spinal deformity following multisegmental instrumentation and arthrodesis.

Authors:  Yongjung J Kim; Keith H Bridwell; Lawrence G Lenke; Kyu-Jung Cho; Charles C Edwards; Anthony S Rinella
Journal:  J Bone Joint Surg Am       Date:  2006-04       Impact factor: 5.284

4.  Use of Recombinant Bone Morphogenetic Protein Is Associated With Reduced Risk of Reoperation After Spine Fusion for Adult Spinal Deformity.

Authors:  Justin C Paul; Baron S Lonner; Shaleen Vira; Ian David Kaye; Thomas J Errico
Journal:  Spine (Phila Pa 1976)       Date:  2016-01       Impact factor: 3.468

Review 5.  A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery.

Authors:  David Benglis; Michael Y Wang; Allan D Levi
Journal:  Neurosurgery       Date:  2008-05       Impact factor: 4.654

6.  Incidence of sacral fractures and in-hospital postoperative complications in the United States: an analysis of 2002-2011 data.

Authors:  Mohamad Bydon; Rafael De la Garza-Ramos; Mohamed Macki; Atman Desai; Aaron K Gokaslan; Ali Bydon
Journal:  Spine (Phila Pa 1976)       Date:  2014-08-15       Impact factor: 3.468

7.  Does recombinant human bone morphogenetic protein-2 use in adult spinal deformity increase complications and are complications associated with location of rhBMP-2 use? A prospective, multicenter study of 279 consecutive patients.

Authors:  Shay Bess; Breton G Line; Virginie Lafage; Frank Schwab; Christopher I Shaffrey; Robert A Hart; Oheneba Boachie-Adjei; Behrooz A Akbarnia; Christopher P Ames; Douglas C Burton; Vedat Deverin; Kai-Ming G Fu; Munish Gupta; Richard Hostin; Khaled Kebaish; Eric Klineberg; Gregory Mundis; Michael O'Brien; Alexis Shelokov; Justin S Smith
Journal:  Spine (Phila Pa 1976)       Date:  2014-02-01       Impact factor: 3.468

8.  Primary Versus Revision Surgery in the Setting of Adult Spinal Deformity: A Nationwide Study on 10,912 Patients.

Authors:  Bassel G Diebo; Peter G Passias; Bryan J Marascalchi; Cyrus M Jalai; Nancy J Worley; Thomas J Errico; Virginie Lafage
Journal:  Spine (Phila Pa 1976)       Date:  2015-11       Impact factor: 3.468

9.  Trends of Posterior Long Segment Fusion with and without Recombinant Human Bone Morphogenetic Protein 2 in Patients with Scoliosis.

Authors:  Yin Ruofeng; Jeremiah R Cohen; Zorica Buser; S Tim Yoon; Hans-Joerg Meisel; Jim A Youssef; Jong-Beom Park; Jeffrey C Wang; Darrel S Brodke
Journal:  Global Spine J       Date:  2015-09-18

10.  Trends in Bone Morphogenetic Protein Usage since the U.S. Food and Drug Administration Advisory in 2008: What Happens to Physician Practices When the Food and Drug Administration Issues an Advisory?

Authors:  Janay Mckie; Sheeraz Qureshi; James Iatridis; Natalia Egorova; Samuel Cho; Andrew Hecht
Journal:  Global Spine J       Date:  2013-12-19
View more
  1 in total

1.  Recombinant Human Bone Morphogenetic Protein-2 Use in Adult Spinal Deformity Surgery: Comparative Analysis and Healthcare Utilization at 24 Months' Follow-up.

Authors:  Nicholas Dietz; Mayur Sharma; Michael Kelly; Beatrice Ugiliweneza; Dengzhi Wang; Joseph Osorio; Isaac Karikari; Doniel Drazin; Maxwell Boakye
Journal:  Global Spine J       Date:  2020-08-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.